Stories about Medizin, Gesundheit

Ottobock SE & Co. KGaA

Ottobock invests in NeuroTech company ONWARD® Medical

Grünenthal Group

First participants enrolled in first-in-human Phase I clinical trial with nociceptin (NOP) receptor agonist

Aachen, Germany (ots) - Today, Grünenthal announced that the first participants have been enrolled in a first-in-human Phase I clinical trial for a nociceptin (NOP) receptor agonist. The trial will include 90 healthy volunteers and aims to demonstrate a favourable safety and tolerability profile and to confirm the ...

PNO Innovation GmbH

Event Announcement: VIROFIGHT Hybrid Symposium

medac Gesellschaft für klinische Spezialpräparate mbH

medac: CDMO medac group at CPHI in Milan

CPHI 2024 CDMO medac group reflects on successful meetings with business partners at CPHI in Milan Medac CDMO group, a reliable partner in contract development and manufacturing, is pleased to report a series of productive and insightful meetings with both current and potential business partners during this year’s CPHI Congress in Milan, held from 8–10 ...

Bertelsmann Stiftung

Better Health Requires More Participation by Young People

Berlin/Gütersloh (ots) - At this year’s World Health Summit in Berlin, the WHO Youth Council presented its vision for healthier societies. The World Health Organization’s Youth Council is calling on policymakers to better leverage the potential of young people. The Bertelsmann Stiftung and major youth organizations support the initiative. Better involvement of and support for young people is essential to creating a ...

STADA Arzneimittel AG

Press Release: EMA accepts Marketing Authorization Applications for AVT03, a Proposed Denosumab Biosimilar

EMA accepts Marketing Authorization Applications for AVT03, a Proposed Denosumab Biosimilar - STADA announces EMA acceptance of Marketing Authorization Applications for AVT03, a proposed denosumab biosimilar to Prolia® (Bone Health) and Xgeva® (Oncology) - STADA holds marketing rights for AVT03 in Europe, as well ...

Helmholtz Munich

Extreme Rainfall Poses Health Risks

Extreme Rainfall Poses Health Risks An international study led by Helmholtz Munich investigates the health consequences of heavy rainfall events. Researchers analyzed the relationship between precipitation patterns and mortality rates at 645 locations across 34 countries from 1980 to 2020. The key finding: Extremely heavy rainfall, which occurs approximately every five years, significantly increases the risk of death, ...

Norgine GmbH

Norgine Announces Appointment of New CEO Janneke van der Kamp

London (ots/PRNewswire) - Norgine (the "Company"), a leading European specialty pharmaceutical company, has today announced the appointment of Janneke van der Kamp as its new Chief Executive Officer (CEO), effective from 1 January 2025. Current CEO, Chris Bath, has stepped down from his role effective immediately. This change in leadership will support and enhance the Company's mission of bringing transformative medicines ...

x-cardiac GmbH

Successful MDR Certification for AI Solution in Predicting Postoperative Complications – New Product Generation for Optimized Patient Safety

Berlin (ots) - x-cardiac, a leader in AI-based medical devices for the prediction of postoperative complications after cardiac surgery, is pleased to announce the successful MDR (Medical Device Regulation) certification of its new x-cardiac-platform. This certification introduces a completely new generation of ...

World Health Summit

German Federal Chancellor Scholz, WHO Director-General Dr Tedros and Bill Gates at the World Health Summit 2024 / The world's leading global health conference begins on October 13

Berlin (ots) - The financing of WHO, Germany's role in global health, antimicrobial resistance, Mpox, digitalization - topics like these are on the agenda of this year's World Health Summit from October 13-15 in Berlin. Leading international experts and decision-makers from all sectors will discuss strategies for a ...

Grünenthal Group

Grünenthal appoints Dr. Jan Adams as Chief Commercial Officer

RHEACELL GmbH und Co. KG

RHEACELL announces FDA approval for Phase 3 study in refractory, non-curable CVU

PNO Innovation GmbH

Launch of canSERV Call for Service Provision – "Training the Next Generation of Cancer Researchers"

PNO Innovation GmbH

Launch of canSERV Call for Service Provision, "Training the Next Generation of Cancer Researchers"

Sysmex Europe SE

2

Fundació Puigvert validates a new tool capable of selecting the most suitable antibiotic for uncomplicated urinary tract infections within 45 minutes.

Fördergesellschaft IZB mbH

2

Record financing rounds at the Munich biotech hub

hubergroup Deutschland GmbH

6

Press Release - hubergroup is Cradle to Cradle certified for the fourth time in a row

Bosch Healthcare Solutions GmbH

Near-patient PCR rapid test for whooping cough for Vivalytic by Bosch now available / World's first fully automated PCR test for detection of B. pertussis, B. parapertussis, B. holmesii

DHL Group

2

PM: DHL Logistics Trend Radar 7.0 beleuchtet neue Entwicklungen in Bereichen wie KI und Nachhaltigkeit / PR: DHL Logistics Trend Radar 7.0 unveils emerging AI trends and sustainable solutions

LAUDA DR. R. WOBSER GMBH & CO. KG

Dr. Ralf Hermann ends career at LAUDA

PNO Innovation GmbH

canSERV relaunches Open Call for Service Provision

STADA Arzneimittel AG

Press release: STADA continues strong growth journey in the first half of 2024

Ottobock SE & Co. KGaA

4

Ottobock in top form – a year full of highlights

Acousia Therapeutics GmbH

Acousia Therapeutics to present its clinical Phase 2 PROHEAR study on hearing loss treatment candidate ACOU085 at upcoming conferences

Tübingen, Germany (ots) - Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, will be presenting the ACOU085 Phase 2 PROHEAR clinical study at the HansonWade 4th Inner Ear Disorders Therapeutics Summit in Boston (MA) from August ...